HPLC Method for Tirzepatide on Primesep B by SIELC Technologies
High Performance Liquid Chromatography (HPLC) Method for Analysis of Tirzepatide
Tirzepatide is a medication primarily used to manage type 2 diabetes and, more recently, for chronic weight management. It is a once-weekly injectable drug that works by activating two hormone receptors:
GLP-1 (Glucagon-like Peptide-1) Receptor: Stimulates insulin secretion, reduces glucagon levels, slows gastric emptying, and reduces appetite.
GIP (Glucose-dependent Insulinotropic Polypeptide) Receptor: Enhances insulin secretion and may improve fat metabolism.
Uses
Type 2 Diabetes: Lowers blood glucose levels and improves glycemic control.
Weight Management: Approved for people with obesity or overweight with related health conditions.
Cardiovascular Risk Reduction: Under investigation for its potential benefits in reducing cardiovascular events.
Common Brand Name
Marketed under the brand name Mounjaro for type 2 diabetes.
Tirzepatide can be retained and analyzed using the Primesep B stationary phase column. The analysis utilizes an isocratic method with a simple mobile phase consisting of water, acetonitrile (MeCN), and TFA. Detection is performed using UV at 280 nm.
| Column | Primesep B, 3.2 x 50 mm, 5 µm, 100 A |
| Mobile Phase | Gradient MeCN – 30-70%, 10 mn |
| Buffer | TFA – 0.1% |
| Flow Rate | 0.5 ml/min |
| Detection | UV 280 nm |
| LOD | 24 ppb |
*LOD was determined for this combination of instrument, method, and analyte, and it can vary from one laboratory to another even when the same general type of analysis is being performed.
| Class of Compounds | Nucleotide Analog Prodrug |
| Analyzing Compounds | Tirzepatide |
Application Column
Primesep B
Column Diameter: 3.2 mm
Column Length: 50 mm
Particle Size: 5 µm
Pore Size: 100 A
